A Phase 4 Study of the Effect on Immune Reconstitution of a Lopinavir/Ritonavir-Based Versus an Efavirenz-Based HAART (Highly Active Antiretroviral Therapy) Regimen in Antiretroviral-Naive Subjects With Advanced HIV Disease.

Trial Profile

A Phase 4 Study of the Effect on Immune Reconstitution of a Lopinavir/Ritonavir-Based Versus an Efavirenz-Based HAART (Highly Active Antiretroviral Therapy) Regimen in Antiretroviral-Naive Subjects With Advanced HIV Disease.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 09 Jul 2014

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lopinavir/ritonavir (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top